One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
Related Stories
Gene therapy restores hearing in about 90% of trial participants / 4 months
Personalized genetic therapy yields improvements in children with rare epilepsy / 5 wks
Ultragenyx gene therapy becomes first FDA‑approved treatment for ultra‑rare disease / 8 days
Fecal capsule transplant reduces peanut allergy in early human and mouse studies / 24 days
Child’s death in Chinese gene‑editing trial kept from public, probe finds / 5 wks
Stem cells show potent promise as a diabetes treatment / 3 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Mergers and Acquisitions, Obesity, Drug Development, Long COVID and look for the RSS link.
StackHealth Time Machine